Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial - Zhong, WZ; Yan, HH; Chen, KN (Signal Transduct Target Ther, 2023)
et al.